Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
"Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A vaccine containing L1 capsid proteins from four types of HPV (ALPHAPAPILLOMAVIRUS), types 6, 11, 16 and 18 that is used to prevent infections from HUMAN PAPILLOMAVIRUSES of these subtypes.
| Descriptor ID |
D000068857
|
| MeSH Number(s) |
D20.215.894.899.498.500
|
| Concept/Terms |
Human Papillomavirus Vaccine L1, Type 6,11,16,18- Human Papillomavirus Vaccine L1, Type 6,11,16,18
- HPV L1 Vaccine, Quadrivalent 6,11,16,18
|
Below are MeSH descriptors whose meaning is more general than "Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18".
Below are MeSH descriptors whose meaning is more specific than "Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18".
This graph shows the total number of publications written about "Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18" by people in this website by year, and whether "Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 0 | 1 | 1 |
| 2017 | 8 | 4 | 12 |
| 2018 | 6 | 1 | 7 |
| 2019 | 2 | 0 | 2 |
| 2020 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18" by people in Profiles.
-
Immunogenicity of 2 and 3 Doses of the Quadrivalent Human Papillomavirus Vaccine up to 120 Months Postvaccination: Follow-up of a Randomized Clinical Trial. Clin Infect Dis. 2020 08 14; 71(4):1022-1029.
-
Durability of the neutralizing antibody response to vaccine and non-vaccine HPV types 7 years following immunization with either Cervarix® or Gardasil® vaccine. Vaccine. 2019 04 24; 37(18):2455-2462.
-
Long-term Antibody Response to Human Papillomavirus Vaccines: Up to 12 Years of Follow-up in the Finnish Maternity Cohort. J Infect Dis. 2019 01 29; 219(4):582-589.
-
Vaccine-preventable anal infections by human papillomavirus among HIV-infected men who have sex with men. Future Microbiol. 2018 10; 13:1463-1472.
-
The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent? Euro Surveill. 2018 10; 23(41).
-
Anogenital human papillomavirus virus DNA and sustained response to the quadrivalent HPV vaccine in women living with HIV-1. Papillomavirus Res. 2018 12; 6:15-21.
-
Risk of Spontaneous Abortion After Inadvertent Human Papillomavirus Vaccination in Pregnancy. Obstet Gynecol. 2018 07; 132(1):35-44.
-
Decline of HPV infections in Scandinavian cervical screening populations after introduction of HPV vaccination programs. Vaccine. 2018 06 18; 36(26):3820-3829.
-
Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development. Vaccine. 2018 08 06; 36(32 Pt A):4792-4799.
-
A 12-Year Follow-up on the Long-Term Effectiveness of the Quadrivalent Human Papillomavirus Vaccine in 4 Nordic Countries. Clin Infect Dis. 2018 01 18; 66(3):339-345.